Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coherus OncologyFRA:8C5 -3.44%61 Cash Ratio is 1.37 as of Jun. 2026, which is 17% below its 10-year median of 1.65. GuruFocus rates FRA:8C5 with a GF Score™ of 61/100 and a GF Value™ of €0.88. The stock has 7 warning signs investors should review. Among 1,318 Biotechnology companies, Coherus Oncology ranks worse than 67.6% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Coherus Oncology Cash Ratio Related Terms
Coherus Oncology Cash Ratio Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs NAUT, AVXL, SLNCF: Cash Ratio Comparison
For the Biotechnology subindustry, Coherus Oncology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a Cash Ratio of 1.37 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Coherus Oncology and its competitors. This is 17% below median its historical median of 1.65. Over the past decade, Coherus Oncology's Cash Ratio has ranged from 0.32 to 7.20. According to the industry distribution chart, Coherus Oncology ranks #891 out of 1318 companies in the Biotechnology industry, placing it in the top 67.6%.
Is Coherus Oncology's Cash Ratio too high?
Coherus Oncology's current Cash Ratio of 1.37 is 17% below median its 10-year median of 1.65. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 7.20. The Biotechnology industry median Cash Ratio is 3.02. Coherus Oncology's value of 1.37 is 54.6% below this industry median. Based on the distribution chart, Coherus Oncology ranks #891 out of 1318 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Coherus Oncology has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Cash Ratio compare to NAUT and AVXL?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #891 out of 1318 companies for Cash Ratio. This places Coherus Oncology in the lower half of its industry. The industry median Cash Ratio is 3.02. Coherus Oncology's value of 1.37 is 54.6% below this benchmark. Historically, Coherus Oncology's own Cash Ratio has ranged from 0.32 to 7.20 over the past decade. While the company's 10-year median is 1.65 vs. the industry median of 3.02, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.02, based on 1,318 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Cash Ratio of 1.37 is 54.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Cash Ratio is 1.37, which is 17% below median its own 10-year median of 1.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Coherus Oncology (FRA:8C5) has a current Cash Ratio of 1.37. The stock's GF Value™ is €0.88, compared to a current price of €1.15 — trading 30.9% above its estimated fair value. The current Cash Ratio is 1.37, which is 17% below median its 10-year median of 1.65 and 54.6% below the Biotechnology industry median of 3.02. Coherus Oncology's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Cash Ratio is 1.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.15 is trading 30.9% above its estimated GF Value™ of €0.88.
Key valuation signals for FRA:8C5:
Cash Ratio: 1.37 (17% below median its 10-year median of 1.65)
GF Value™: €0.88 vs. price of €1.15 (30.9% above fair value)
Industry Position: 54.6% below the Biotechnology median (#891 of 1318)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
61GF Score
Get the complete analysis for FRA:8C5
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
